Impressive Results of Dulaglutide in Preventing Cardiovascular Events

The Importance of Cardiovascular Health for Diabetic Patients

Individuals with type 2 diabetes face a significantly increased risk of cardiovascular events, being twice as likely to experience heart attacks and strokes. Additionally, approximately 40% of these individuals develop kidney disease.

Understanding Dulaglutide

Dulaglutide is a glucagon-like peptide-1 analog that enhances incretin levels, a metabolic hormone that stimulates insulin production following meals. This medication also slows stomach emptying and reduces sugar absorption into the bloodstream. Administered once a week via injection, dulaglutide is approved for use globally, including in Canada.

Details of the REWIND Trial

Recent research, known as the Researching Cardiovascular Events with a Weekly Incretin Diabetes (REWIND) trial, has highlighted the effectiveness of dulaglutide. The findings have been published in two papers focusing on cardiovascular and kidney outcomes.

The trial encompassed 9,900 participants across 24 countries over more than five years. All subjects were middle-aged or older individuals diagnosed with type 2 diabetes, with about 46% being women. Notably, over two-thirds of the participants had no prior cardiovascular disease.

Key Findings of the Trial

Participants treated with dulaglutide exhibited a 12% reduction in the risk of cardiovascular events, such as heart attacks and strokes, compared to those receiving a placebo. This benefit was consistent across genders and regardless of prior cardiovascular issues. Furthermore, dulaglutide contributed to a 15% decrease in the onset of kidney disease.

In addition to these cardiovascular benefits, dulaglutide also facilitated weight loss, lowered blood pressure, and reduced low-density lipoprotein (LDL) cholesterol levels. The most frequently reported side effects were gastrointestinal issues, with 47% of patients experiencing symptoms like constipation and diarrhea, compared to 34% in the placebo group.

References

Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, MD et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. Published: June 09, 2019.

EurekAlert!. (2019). Large international study finds diabetes drug cuts cardiovascular and kidney problems. [online] Available at: https://www.eurekalert.org/pub_releases/2019-06/mu-lis060619.php [Accessed 10 Jun. 2019].